John Farley
Distinguished in Virilizing Ovarian Tumor

Dr. John Farley

Obstetrics and Gynecology | Oncology
CommonSpirit Health
Dignity Health Cancer Institute At St. Joseph's
625 N 6th Street, 
Phoenix, AZ 
Accepting New Patients
Offers Telehealth

Distinguished in Virilizing Ovarian Tumor
CommonSpirit Health
Dignity Health Cancer Institute At St. Joseph's
625 N 6th Street, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Farley, MD, COL(Ret), is a board certified gynecologic oncologist in the Division of Gynecologic Oncology and the Department of Obstetrics and Gynecology with Dignity Health Medical Group. He is part of the Comprehensive Cancer Center and is board certified in Obstetrics and Gynecology with a subspecialty certification in Gynecologic Oncology.Dr. Farley's expertise includes clinical trial design, new drug development, and treatment of complex gynecologic malignancies. He is a member of the Gynecologic Oncology Group, American Association of Cancer Research, Society of Gynecologic Oncologists, American Society of Clinical Oncology and is a Fellow of the American Congress of Obstetricians and Gynecologist. Additionally, Dr. Farley is a highly decorated Colonel in the Army, awarded the Bronze Star Medal in 2005 and Meritorious Service Medal in 2006. Dr. Farley received his undergraduate degree from the United States Military Academy. He then received his medical degree from Uniformed Services University of the Health Sciences. He subsequently completed his residency in Obstetrics and Gynecology and fellowship in Gynecologic Oncology at Walter Reed Army Medical Center.My mission, along with the St. Joseph Medical Group, is to focus on innovative clinical care and the pursuit of excellence through scholarly activities. This allows me to provide patients with state-of-the-art patient services and exceptional patient experiences.

Dr. Farley is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Lymphadenectomy, and Hysterectomy.

His clinical research consists of co-authoring 67 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Unif. Svs Univ Of Health Sciences
Specialties
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in AZ
Board Certifications
OB & Gyn (Sub: Gynecologic Oncology)
Obstetrics & Gynecology
Fellowships
Walter Reed Army Medical Center
Hospital Affiliations
Dignity Health St. Joseph's Hospital And Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Dignity Health Cancer Institute at St. Joseph's
625 N 6th Street, Phoenix, AZ 85004
Call: 602-406-8222

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


10 Clinical Trials

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Dactinomycin, Leucovorin Calcium, Methotrexate
Study Phase: Phase 3
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase II Trial of AZD6244 (NSC# 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Phase II Trial of AZD6244 (NSC# 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Completed
Publish Date: December 03, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum
A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum
Enrollment Status: Completed
Publish Date: March 10, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
View 9 Less Clinical Trials

67 Total Publications

Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609 (Cohort 38).
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609 (Cohort 38).
Journal: Journal for immunotherapy of cancer
Published: October 01, 2025
View All 67 Publications
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Mike F. Janicek
Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Mike F. Janicek
Oncology | Obstetrics and Gynecology

Arizona Oncology Associates, PC

10197 N 92nd St, Ste 101, 
Scottsdale, AZ 
 (13.4 miles away)
480-993-2950
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mike Janicek is an Oncologist and an Obstetrics and Gynecologist in Scottsdale, Arizona. Dr. Janicek is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, Ovarian Cancer, Oophorectomy, and Hernia Surgery.

Mario J. Pineda
Distinguished in Virilizing Ovarian Tumor
Dr. Mario J. Pineda
Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Mario J. Pineda
Oncology | Obstetrics and Gynecology

Ironwood Physicians, PC

3686 S Rome Street, 
Gilbert, AZ 
 (24.5 miles away)
480-890-7705
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Pineda joined Ironwood Cancer & Research Centers in August 2017.  Dr. Mario Javier Pineda is fellowship trained in Gynecologic Oncology and board certified in Obstetrics and Gynecology.  He is a first-generation Salvadoran-American fluent in both English and Spanish.  Dr. Pineda received his medical training at the University of Washington School Of Medicine.  While there he also obtained a PhD in Molecular and Cellular Biology.  He then completed an Obstetrics and Gynecology residency at the Los Angeles County & University of Southern California Medical Center in 2011 where he served as Chief Resident.  Dr. Pineda finished his training with a fellowship in Gynecologic Oncology at Northwestern University.Dr. Pineda offers women with gynecologic cancers a comprehensive approach to their care including radical pelvic and vulvar surgery, advanced minimally invasive and robotic procedures, and laser surgery.  Areas of specialty include treatment of ovarian, fallopian, primary peritoneal and uterine cancers; cervical, vulvar and vaginal cancer (including pre-invasive lesions); and gestational trophoblastic disease.  He has extensive experience in chemotherapeutic and clinical trial management of patients.He is an active member of the American Society of Clinical Oncologists, the Society of Gynecologic Oncologists and the American Congress of Obstetricians and Gynecologists.Dr. Pineda offers women with gynecologic cancers a comprehensive approach to their care including radical pelvic and vulvar surgery, advanced minimally invasive and robotic procedures, and laser surgery.  Areas of specialty include treatment of ovarian, fallopian, primary peritoneal and uterine cancers; cervical, vulvar and vaginal cancer (including pre-invasive lesions); and gestational trophoblastic disease.  He has extensive experience in chemotherapeutic and clinical trial management of patients. Dr. Pineda is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Lump in the Abdomen, Malignant Mixed Mullerian Tumor, and Endometrial Cancer.

Snehal M. Bhoola
Distinguished in Virilizing Ovarian Tumor
Dr. Snehal M. Bhoola
Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Snehal M. Bhoola
Oncology | Obstetrics and Gynecology

Cancer & Blood Specialists Of Arizona

1501 N Gilbert Road, Suite 200, 
Gilbert, AZ 
 (18.3 miles away)
480-530-4220
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Snehal Bhoola is an Oncologist and an Obstetrics and Gynecologist in Gilbert, Arizona. Dr. Bhoola is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Bladder Reconstruction, and Oophorectomy. Dr. Bhoola is currently accepting new patients.

VIEW MORE VIRILIZING OVARIAN TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Farley's expertise for a condition
ConditionClose
    • Distinguished
    • Cervical Cancer
      Dr. Farley is
      Distinguished
      . Learn about Cervical Cancer.
      See more Cervical Cancer experts
    • Ovarian Cancer
      Dr. Farley is
      Distinguished
      . Learn about Ovarian Cancer.
      See more Ovarian Cancer experts
    • Ovarian Carcinosarcoma
      Dr. Farley is
      Distinguished
      . Learn about Ovarian Carcinosarcoma.
      See more Ovarian Carcinosarcoma experts
    • Testicular Yolk Sac Tumor
      Dr. Farley is
      Distinguished
      . Learn about Testicular Yolk Sac Tumor.
      See more Testicular Yolk Sac Tumor experts
    • Virilizing Ovarian Tumor
      Dr. Farley is
      Distinguished
      . Learn about Virilizing Ovarian Tumor.
      See more Virilizing Ovarian Tumor experts
    • Advanced
    • Adult Soft Tissue Sarcoma
      Dr. Farley is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Desmoplastic Small Round Cell Tumor
      Dr. Farley is
      Advanced
      . Learn about Desmoplastic Small Round Cell Tumor.
      See more Desmoplastic Small Round Cell Tumor experts
    • Endometrial Cancer
      Dr. Farley is
      Advanced
      . Learn about Endometrial Cancer.
      See more Endometrial Cancer experts
    • Endometrial Stromal Sarcoma
      Dr. Farley is
      Advanced
      . Learn about Endometrial Stromal Sarcoma.
      See more Endometrial Stromal Sarcoma experts
    • Malignant Mixed Mullerian Tumor
      Dr. Farley is
      Advanced
      . Learn about Malignant Mixed Mullerian Tumor.
      See more Malignant Mixed Mullerian Tumor experts
    • Neuroendocrine Carcinoma of the Cervix
      Dr. Farley is
      Advanced
      . Learn about Neuroendocrine Carcinoma of the Cervix.
      See more Neuroendocrine Carcinoma of the Cervix experts
    View All 7 Advanced Conditions
    • Experienced
    • BRCA Positive Breast Cancer
      Dr. Farley is
      Experienced
      . Learn about BRCA Positive Breast Cancer.
      See more BRCA Positive Breast Cancer experts
    • Cervical Dysplasia
      Dr. Farley is
      Experienced
      . Learn about Cervical Dysplasia.
      See more Cervical Dysplasia experts
    • HER2 Negative Breast Cancer
      Dr. Farley is
      Experienced
      . Learn about HER2 Negative Breast Cancer.
      See more HER2 Negative Breast Cancer experts
    • Hydrocele
      Dr. Farley is
      Experienced
      . Learn about Hydrocele.
      See more Hydrocele experts
    • Hysterectomy
      Dr. Farley is
      Experienced
      . Learn about Hysterectomy.
      See more Hysterectomy experts
    • Li-Fraumeni Syndrome
      Dr. Farley is
      Experienced
      . Learn about Li-Fraumeni Syndrome.
      See more Li-Fraumeni Syndrome experts
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.